Sanofi is handing back a phase 2-stage natural killer (NK) cell engager and canceling another cancer trial as the Big Pharma ...

After selling off a portion of its diabetes care business last year, Ypsomed is now fully exiting the diabetes care business ...

Biolinq has raised $100 million in venture capital financing to help complete the development of its wearable glucose ...

BD is rolling out a new monitoring platform equipped with artificial-intelligence-powered programs that aim to predict ...

Harvard University is suing President Trump's administration over its threats to freeze billions in research funding. | Harvard University is suing President Trump's administration over its threats to ...

Roche’s drug production operations are set to benefit from the company’s updated U.S. strategy, including with “expanded and ...

The National Institutes of Health (NIH) is halting new grant and contract payments to several universities, a move the agency ...

The mandate overrules Section 4.1.2 “Civil Rights Protections” of the NIH Grants Policy Statement, which includes the Civil ...

Tempest Therapeutics is hunkering down to weather the storm that has engulfed its operations. | Tempest Therapeutics is ...

It’s been five years since the U.K.’s breakup with the European Union, and the impacts of extra red tape and rising costs ...

That means the future of Roivant is tied to the success, or otherwise, of Immunovant’s attempts to break into the FcRn market ...

Medtronic has secured a green light from the FDA to connect its latest automated insulin pump with its newest continuous ...